Upjohn Company Profile

✉ Email this page to a colleague

UPJOHN has thirteen approved drugs.

There are three US patents protecting UPJOHN drugs.

There are thirty-three patent family members on UPJOHN drugs in thirty-three countries and thirty-nine supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-003	Aug 29, 2002	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-001	Dec 30, 2004	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-007	Dec 30, 2004	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-003	Oct 20, 1997	6,274,171*PED	⤷ Sign Up
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-002	Sep 27, 2002	6,534,093*PED	⤷ Sign Up
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-002	Dec 31, 1998	5,563,165*PED	⤷ Sign Up
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	5,422,368	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Solution	20 mg/mL	➤ Subscribe	2010-05-19
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Extended-release Tablets	37.5 mg, 75 mg and 150 mg	➤ Subscribe	2007-05-03
➤ Subscribe	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg	➤ Subscribe	2008-12-30
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2006-09-27
➤ Subscribe	Extended-release Capsules	2 mg and 4 mg	➤ Subscribe	2007-07-30
➤ Subscribe	Capsules	50 mg	➤ Subscribe	2008-03-21

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0247633	62/1997	Austria	⤷ Sign Up	PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0364417	SPC/GB97/014	United Kingdom	⤷ Sign Up	PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
3461484	2021C/515	Belgium	⤷ Sign Up	PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
1003503	SZ 30/2006	Austria	⤷ Sign Up	PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.